8-K: Rhythm Pharmaceuticals Reports Positive Q1 2025 Results and Advances Hypothalamic Obesity Program

Rhythm Pharmaceuticals announced positive first quarter 2025 financial results, highlighted by strong IMCIVREE sales and progress in their setmelanotide and bivamelagon clinical programs.

Summary

• Rhythm Pharmaceuticals reported Q1 2025 financial results and provided a business update.
• Net product revenue from global sales of IMCIVREE (setmelanotide) was $37.7 million in Q1 2025, compared to $26.0 million in Q1 2024.
• The number of patients on reimbursed therapy increased 14% in Q1 2025 compared to Q4 2024.
• U.S. revenue was $24.5 million, affected by an $8.3 million decrease in inventory at a specialty pharmacy and a $1.1 million increase in product dispensed to patients, resulting in a net decrease in U.S. product revenue of $7.2 million compared to the fourth quarter of 2024.
• Revenue outside the U.S. was $13.2 million, an increase of $3.2 million quarter over quarter.
• The Phase 3 TRANSCEND trial of setmelanotide in acquired hypothalamic obesity (HO) met its primary endpoint with a -19.8% placebo-adjusted BMI reduction.
• U.S. and EU regulatory submissions for setmelanotide in acquired HO are on track to be completed in Q3 2025.
• Topline data from the Phase 2 trial of oral MC4R agonist bivamelagon is expected in Q3 2025.
• Rhythm reacquired the rights to IMCIVREE in China.
• Rhythm received orphan drug designation from Japan for setmelanotide as a treatment for acquired hypothalamic obesity.
• Cash, cash equivalents, and short-term investments were approximately $314.5 million as of March 31, 2025.
• The company expects its cash to support planned operations into 2027.
• Net loss attributable to common stockholders was ($50.8) million for Q1 2025, compared to ($141.4) million for Q1 2024.
• The company anticipates approximately $285 million to $315 million in Non-GAAP Operating Expenses for the year ending December 31, 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, successful clinical trial results, and a healthy cash position. The company is progressing towards regulatory submissions and has a clear path to potential future growth.

Positives

• Strong growth in IMCIVREE sales, with $37.7 million in Q1 2025.
• Positive results from the Phase 3 TRANSCEND trial for setmelanotide in acquired hypothalamic obesity.
• Advancement of the bivamelagon program with topline data expected soon.
• Reacquisition of IMCIVREE rights in China.
• Orphan drug designation in Japan for setmelanotide.
• Healthy cash position to fund operations into 2027.
• Decrease in net loss compared to the same quarter last year.

Negatives

• U.S. revenue was affected by an $8.3 million decrease in inventory at the specialty pharmacy that dispenses IMCIVREE to patients and a $1.1 million increase in product dispensed to patients, resulting in a net decrease in U.S. product revenue of $7.2 million compared to the fourth quarter of 2024.
• License revenue decreased due to the termination of the RareStone Group Ltd. agreement, resulting in a negative $5.0 million impact.

Risks

• Reliance on successful regulatory submissions and approvals for setmelanotide.
• Potential challenges in commercializing IMCIVREE in China after reacquiring the rights.
• Uncertainty surrounding the outcome of ongoing clinical trials.
• Dependence on third-party manufacturers and suppliers.
• Competition from other companies developing treatments for obesity and related conditions.

Future Outlook

Rhythm expects to submit regulatory applications for setmelanotide in acquired hypothalamic obesity in Q3 2025 and anticipates its current cash position will fund operations into 2027.

Management Comments

• David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm, stated that the company looks forward to completing U.S. and EU regulatory submissions in the third quarter of 2025 and bringing the first-ever approved therapy for acquired hypothalamic obesity to patients.
• Dr. Meeker also mentioned that Rhythm is advancing its next-generation MC4R agonists and expects topline data from the Phase 2 trial evaluating bivamelagon in patients with HO in the third quarter of 2025.
• Dr. Meeker noted the continued growth in the number of patients on reimbursed therapy with BBS and the strong performance internationally.
• Dr. Meeker believes Rhythm is well capitalized with a cash runway into 2027, beyond multiple clinical and regulatory milestones expected this year and early next year.

Industry Context

Rhythm Pharmaceuticals is focused on rare neuroendocrine diseases, specifically obesity caused by genetic deficiencies or acquired conditions. The company's lead product, IMCIVREE, targets the MC4R pathway, a key regulator of appetite and energy expenditure. The positive results from the TRANSCEND trial and the advancement of bivamelagon position Rhythm as a leader in the development of therapies for hypothalamic obesity, an area with significant unmet medical need.

Comparison to Industry Standards

• The -19.8% placebo-adjusted BMI reduction in the TRANSCEND trial is a clinically meaningful result compared to other obesity treatments.
• Companies like Novo Nordisk and Eli Lilly are developing and marketing GLP-1 receptor agonists for general obesity, but Rhythm is focused on addressing the underlying genetic or acquired causes of obesity in specific patient populations.
• Other companies such as Amryt Pharma (now Chiesi) have focused on rare endocrine disorders, but Rhythm's focus on the MC4R pathway and its pipeline of MC4R agonists differentiate it from its peers.

Stakeholder Impact

• Positive impact on patients with rare neuroendocrine diseases through the development of new therapies.
• Potential for increased shareholder value through revenue growth and successful clinical development.
• Continued employment opportunities and potential for company expansion.

Next Steps

• Submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency for setmelanotide for the treatment of acquired HO in the third quarter of 2025.
• Announce topline data from the bivamelagon Phase 2 trial in acquired HO in the third quarter of 2025.
• Complete enrollment in the setmelanotide Phase 2 trial in Prader-Willi syndrome (PWS) in the second half of 2025.
• Complete enrollment in the Phase 1, Part C trial evaluating the weekly, MC4R agonist RM-718 in patients with acquired hypothalamic obesity in the second half of 2025.
• Complete enrollment in the setmelanotide Phase 3 trial substudy in congenital hypothalamic obesity in the second half of 2025.
• Announce topline data in the 12-patient Japanese cohort of the setmelanotide Phase 3 trial in acquired HO in the first quarter of 2026.
• Announce topline data in the Phase 3 EMANATE trial evaluating setmelanotide in genetically caused MC4R pathway diseases in the first quarter of 2026.

Key Dates

Keywords

setmelanotide, IMCIVREE, hypothalamic obesity, bivamelagon, Rhythm Pharmaceuticals, financial results, clinical trials, regulatory submissions, neuroendocrine diseases, obesity